CHatGDT (AI annalysis) Good for a laugh.
Oncology (ASX: RAC) is a biotechnology company focused on cancer treatment, with its lead product, bisantrene, being developed for various oncology indications. The company's stock has shown a mix of bullish and bearish signals in recent analyses.As of recent data, the share price was around 1.745 AUD, with predictions indicating a potential drop to 0.639 AUD, representing a significant decrease of about 63% over the next year. This suggests a bearish outlook for the stock in the near future [oai_citation:1,Race Oncology Ltd (RAC) Share Price Forecast & Price Target - Investing.com UK](https://uk.investing.com/equities/race-oncology-ltd-consensus-estimates) [oai_citation:2,Race Oncology Ltd, RAC:ASX forecasts - FT.com](https://markets.ft.com/data/equities/tearsheet/forecasts?s=RAC:ASX) [oai_citation:3,Race Oncology Stock Forecast: down to 0.639 AUD? - RAC Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis](https://walletinvestor.com/asx-stock-forecast/rac-stock-prediction).Technical analysis indicates that the stock might experience short-term fluctuations, with support levels at around 1.720 AUD and resistance levels at 1.800 AUD. The stock's moving averages also suggest a potential downward trend, with the 200-day moving average significantly lower than the current price, pointing to a bearish sentiment [oai_citation:4,Race Oncology Stock Forecast: down to 0.639 AUD? - RAC Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis](https://walletinvestor.com/asx-stock-forecast/rac-stock-prediction).Despite this, some analysts have given it a "Strong Buy" rating based on its recent performance and technical indicators, which could mean potential for short-term gains for risk-tolerant investors [oai_citation:5,Race Oncology Ltd (RAC) Share Price Forecast & Price Target - Investing.com UK](https://uk.investing.com/equities/race-oncology-ltd-consensus-estimates) [oai_citation:6,Race Oncology Ltd, RAC:ASX forecasts - FT.com](https://markets.ft.com/data/equities/tearsheet/forecasts?s=RAC:ASX).In summary, while Race Oncology has promising products in its pipeline, the share price projections are currently mixed, with a significant risk of decline. Investors should carefully consider these factors and perhaps look for other investment opportunities if they are risk-averse.
- Forums
- ASX - By Stock
- RAC
- RAC - Charts & Price Action
RAC - Charts & Price Action, page-21377
-
- There are more pages in this discussion • 1,204 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.63 |
Change
-0.063(3.70%) |
Mkt cap ! $277.7M |
Open | High | Low | Value | Volume |
$1.66 | $1.66 | $1.57 | $266.8K | 163.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 574 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.63 | 6622 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 574 | 1.625 |
1 | 2500 | 1.620 |
1 | 2000 | 1.610 |
1 | 625 | 1.600 |
1 | 862 | 1.595 |
Price($) | Vol. | No. |
---|---|---|
1.630 | 6622 | 1 |
1.635 | 10000 | 1 |
1.640 | 1880 | 2 |
1.650 | 1400 | 1 |
1.655 | 4713 | 1 |
Last trade - 14.37pm 04/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |